Inhibitor of histone deacetylases
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Oxamflatin

Item No. 13176

Technical Information
Formal Name
N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2E-penten-4-ynamide
CAS Number
151720-43-3
Synonyms
  • Metacept 3
Molecular Formula
C17H14N2O4S
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 10 mg/mlDMF:PBS (pH 7.2) (1:10): 0.1 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.1 mg/mlEthanol: 0.5 mg/ml
λmax
241, 296 nm
SMILES
O=S(NC1=CC(C#C/C=C/C(NO)=O)=CC=C1)(C2=CC=CC=C2)=O
InChi Code
InChI=1S/C17H14N2O4S/c20-17(18-21)12-5-4-7-14-8-6-9-15(13-14)19-24(22,23)16-10-2-1-3-11-16/h1-3,5-6,8-13,19,21H,(H,18,20)/b12-5+
InChi Key
QRPSQQUYPMFERG-LFYBBSHMSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Oxamflatin is a potent inhibitor of histone deacetylases (IC50 = 15.7 nM).1 It has been shown to alter the expression of several genes whose products are involved in cell morphology, motility, apoptosis, and cell cycle control, reducing the proliferation of cancer cells.1,2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kim, Y.B., Lee, K.H., Sugita, K., et alOxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18(15), 2461-2470 (1999).

    2. Peart, M.J., Tainton, K.M., Ruefli, A.A., et alNovel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63(15), 4460-4471 (2003).

    3. Dear, A.E., and Medcalf, R.L. The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity. Biochim. Biophys. Acta 1492(1), 15-22 (2000).